Vaxil Bio Ltd. (TSXV:VXL)
Canada
· Delayed Price · Currency is CAD | Market Cap | 637.44K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -70.00K |
| Shares Out | 3.98M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,040 |
| Average Volume | 4,711 |
| Open | 0.140 |
| Previous Close | 0.140 |
| Day's Range | 0.140 - 0.160 |
| 52-Week Range | 0.130 - 0.325 |
| Beta | -1.24 |
| RSI | 62.75 |
| Earnings Date | Apr 23, 2026 |
About Vaxil Bio
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada. [Read more]
Financial Performance
Financial StatementsNews
Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company completed its previously announced non-brokered private...
Vaxil Announces Non-Brokered Private Placement
NESS-ZIONA, ISRAEL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company intends to complete a non-brokered private p...